Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

David Marín; Katayoun Rezvani; Jeffrey M. Wilson; Nadima Uprety; Muzaffar H. Qazilbash; Roland L. Bassett; Yago Nieto; Vakul Mohanty; Rafet Başar; Loretta J. Nastoupil; Hind Rafei; Kai Cao; Pinaki P. Banerjee; Richard E. Champlin; Chitra Hosing; Elizabeth J. Shpall; Mayra Shanley; May Daher; Uday Popat; Partow Kebriaei; Homer A. Macapinlac; Mecit Kaplan; Sadie Mae Moseley; Christopher R. Flowers; Paul Lin; Mariam Ammari; Ye Li; Ken Chen; Jinzhuang Dou; Sunil Acharya; Enli Liu; Sonny Ang; Sheetal Rao; Peter F. Thall; Christina Ganesh; Merve Dede

doi:10.1038/s41591-023-02785-8

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

David Marín(Hammersmith Hospital), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center), Jeffrey M. Wilson(The University of Texas MD Anderson Cancer Center), Nadima Uprety(The University of Texas MD Anderson Cancer Center), Muzaffar H. Qazilbash(The University of Texas MD Anderson Cancer Center), Roland L. Bassett(The University of Texas MD Anderson Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Vakul Mohanty(The University of Texas MD Anderson Cancer Center), Rafet Başar(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Hind Rafei(The University of Texas MD Anderson Cancer Center), Kai Cao(The University of Texas MD Anderson Cancer Center), Pinaki P. Banerjee(The University of Texas MD Anderson Cancer Center), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Chitra Hosing(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Mayra Shanley(The University of Texas MD Anderson Cancer Center), May Daher(The University of Texas MD Anderson Cancer Center), Uday Popat(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Homer A. Macapinlac(International Atomic Energy Agency), Mecit Kaplan(The University of Texas MD Anderson Cancer Center), Sadie Mae Moseley(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Paul Lin(The University of Texas MD Anderson Cancer Center), Mariam Ammari(The University of Texas MD Anderson Cancer Center), Ye Li(Nanjing University of Chinese Medicine), Ken Chen(Center for Personalized Cancer Treatment), Jinzhuang Dou(The University of Texas MD Anderson Cancer Center), Sunil Acharya(The University of Texas MD Anderson Cancer Center), Enli Liu(The University of Texas MD Anderson Cancer Center), Sonny Ang(The University of Texas MD Anderson Cancer Center), Sheetal Rao(The University of Texas MD Anderson Cancer Center), Peter F. Thall(The University of Texas MD Anderson Cancer Center), Christina Ganesh(The University of Texas MD Anderson Cancer Center), Merve Dede(The University of Texas MD Anderson Cancer Center)

Nature Medicine

January 18, 2024

10.1038/s41591-023-02785-8

Cited by 452

Related Papers

The Immune Landscape of Cancer

|Immunity|2018|6.2k

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

|Journal of Clinical Oncology|2018|3.7k

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

|Journal of Clinical Oncology|1997|1.3k

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

|Blood|1997|1.2k

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

|New England Journal of Medicine|2012|1.1k